Brazil Genetic Testing Market Size, Share, Trends, Forecast, Growth, Outlook, Insight, Report 2026-2034

Market Overview

The Brazil genetic testing market reached USD 462.1 Million in 2025 and is projected to grow to USD 1,013.6 Million by 2034. The market is expected to expand at a CAGR of 9.12% during the forecast period of 2026-2034. Growth drivers include rising awareness of genetic disorders, increasing adoption of personalized medicine, expanding genomic research, technological advancements, and government initiatives. The demand for pre- and post-natal genetic screening is also fueling the market.

Study Assumption Years

• Base Year: 2025
• Historical Year/Period: 2020-2025
• Forecast Year/Period: 2026-2034

Brazil Genetic Testing Market Key Takeaways

• The market size reached USD 462.1 Million in 2025 with a forecast to USD 1,013.6 Million by 2034.
• The market is growing at a CAGR of 9.12% between 2026 and 2034.
• Increasing awareness of genetic disorders through education and programs is a prominent growth factor.
• Personalized medicine adoption is enhancing the use of genetic testing in therapies, especially in oncology, cardiology, and neurology.
• Collaborations such as MGI Tech Co., Ltd. with Sabin Group are boosting genomic solutions accessibility in Brazil.
• Expanding research on genetic factors in diseases like pancreatic cancer is improving understanding and testing demand.

Sample Request Link: https://www.imarcgroup.com/brazil-genetic-testing-market/requestsample

Market Growth Factors

Growing awareness towards hereditary disorders and genetic testing services and increasing efforts to educate the audience regarding hereditary disorders and genetic susceptibility testing are the factors responsible for the growth of the Brazil genetic testing market. Governmental and non-profit organizations have also contributed. A 9 December 2025 study by the São Paulo State Cancer Institute identified pathogenic germline variants in 6.25% of patients with pancreatic ductal adenocarcinoma, adding to the growing knowledge of genetic risk factors for the disease. This is associated with increased health checkups related to genetics.

Precision medicine practice, also called personalized medicine, is a major driver because genetic testing helps physicians use more effective medicines that have lower side effects depending on the patient's genes. This is especially the case within oncology, cardiology, and neurology, with clinically useful genomic tests enabling accurate diagnosis and targeted treatment. On December 4, 2025, MGI Tech Co., Ltd. partnered with Sabin Group to improve access and quality of personalized medicine nationwide via advanced genomic solutions.

The driver of the Brazilian market for genetic tests is the rising demand for fast and innovative health interventions, growing research into genetic diseases and the consumers' awareness. Health information through government and private initiatives increases the consumers' knowledge about disease prevention, and genetic testing is a sought after topic. Private companies engaging in partnerships between genetic testing labs and biopharmaceutical companies also help expand precision health into the commercial sector, as do government initiatives and emerging areas of genomic research.

Market Segmentation

• Test Type: Prenatal Testing, Carrier Testing, New Born Testing, Predictive/Presymptomatic Testing, Diagnostic Testing, Others. These categories cover a wide range of genetic tests addressing various patient needs.
• Disease: Cancer, Down Syndrome, Thalassemia, Others. This segmentation highlights disease-specific genetic testing focus areas.
• Technology: Biochemical, Molecular, Cytogenetic. The market includes different genetic testing technologies to address specific diagnostic requirements.
• Service Provider: Hospital Based, Independent Laboratories, Specialty Clinic. Providers vary by the facility type offering genetic testing services.
• Testing Sample: Blood, Saliva, Hair, Others. Samples collected for genetic testing vary, enabling flexibility in testing protocols.

Regional Insights

The Brazil genetic testing market analysis covers major regions including Southeast, South, Northeast, North, and Central-West. The report provides a comprehensive assessment of these key regional markets, noting their individual contributions without specifying explicit market shares or CAGR values. This regional breakdown supports localized market strategies and development planning.

Recent Developments & News

• On September 16, 2025, PlexBio Co., Ltd. announced a strategic partnership with Biomédica Brazil to deliver molecular diagnostic products and the πCode® detection platform for cancer gene mutation testing across Brazil, enhancing access to precision medicine.
• On September 18, 2025, MGI Tech partnered with Dasa, Latin America's largest medical diagnostics company, to improve health diagnosis through genetic sequencing in Brazil, aiming to elevate precision in diagnosing cancer and rare diseases.

Key Players

• PlexBio Co., Ltd.
• Biomédica Brazil
• MGI Tech Co., Ltd.
• Sabin Group
• Dasa

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request Customization:- https://www.imarcgroup.com/request?type=report&id=29889&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302